TPO for ITP in pregnancy.

J. Bussel,Eun-Ju Lee

DOI: https://doi.org/10.1182/blood-2017-07-793356

IF: 20.3

2017-08-31

Blood

Abstract:In this issue of Blood , Kong et al describe a novel approach to immune thrombocytopenia (ITP) in pregnancy. 1

What problem does this paper attempt to address?

Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity

Patrice D. Cani,Melania Osto,Lucie Geurts,Amandine Everard

DOI: https://doi.org/10.4161/gmic.19625

IF: 12.2

2012-07-14

Gut Microbes

Abstract:Obesity is associated with metabolic alterations related to glucose homeostasis and cardiovascular risk factors. These metabolic alterations are associated with low-grade inflammation that contributes to the onset of these diseases. We and others have provided evidence that gut microbiota participates in whole-body metabolism by affecting energy balance, glucose metabolism, and low-grade inflammation associated with obesity and related metabolic disorders. Recently, we defined gut microbiota-derived lipopolysaccharide (LPS) (and metabolic endotoxemia) as a factor involved in the onset and progression of inflammation and metabolic diseases. In this review, we discuss mechanisms involved in the development of metabolic endotoxemia such as the gut permeability. We also discuss our latest discoveries demonstrating a link between the gut microbiota, endocannabinoid system tone, leptin resistance, gut peptides (glucagon-like peptide-1 and -2), and metabolic features. Finally, we will introduce the role of the gut microbiota in specific dietary treatments (prebiotics and probiotics) and surgical interventions (gastric bypass).

gastroenterology & hepatology,microbiology
Gut Barrier Dysfunction and Bacterial Lipopolysaccharides in Colorectal Cancer

Qiang Li,Viktor von Ehrlich-Treuenstätt,Josefine Schardey,Ulrich Wirth,Petra Zimmermann,Joachim Andrassy,Alexandr V Bazhin,Jens Werner,Florian Kühn

DOI: https://doi.org/10.1007/s11605-023-05654-4

Abstract:Background: Inflammation is known to be an essential driver of various types of cancer. An increasing number of studies have suggested that the occurrence and development of colorectal cancer (CRC) are linked to the inflammatory microenvironment of the intestine. This assumption is further supported by the fact that patients with inflammatory bowel disease (IBD) are more likely to develop CRC. Multiple studies in mice and humans have shown that preoperative systemic inflammatory response is predictive of cancer recurrence after potentially curative resection. Lipopolysaccharides (LPS) are membrane surface markers of gram-negative bacteria, which induce gut barrier dysfunction and inflammation and might be significantly involved in the occurrence and development of CRC. Methods: A selective literature search was conducted in Medline and PubMed, using the terms "Colorectal Cancer", "Gut Barrier", "Lipopolysaccharides", and "Inflammation". Results: Disruption of intestinal homeostasis, including gut barrier dysfunction, is linked to increased LPS levels and is a critical factor for chronic inflammation. LPS can activate the diverse nuclear factor-κB (NF-κB) pathway via Toll-like receptors 4 (TLR4) to promote the inflammatory response, which aggravates gut barrier dysfunction and encourages CRC development. An intact gut barrier prevents antigens and bacteria from crossing the intestinal endothelial layer and entering circulation. In contrast, a damaged gut barrier triggers inflammatory responses and increases susceptibility to CRC. Thus, targeting LPS and the gut barrier might be a promising novel therapeutic approach for additional treatment of CRC. Conclusion: Gut barrier dysfuction and bacterial LPS seem to play an important role in the pathogenesis and disease progression of colorectal cancer and therefore require further investigation.
Iterative learning control for output-constrained systems with both parametric and nonparametric uncertainties

Xu Jin,Jian-xin Xu

DOI: https://doi.org/10.1016/j.automatica.2013.04.039

2013-08-01

at - Automatisierungstechnik

Abstract:
Regulation of Gut Microbiota and Metabolic Endotoxemia with Dietary Factors

Nobuo Fuke,Naoto Nagata,Hiroyuki Suganuma,Tsuguhito Ota

DOI: https://doi.org/10.3390/nu11102277

IF: 5.9

2019-09-23

Nutrients

Abstract:Metabolic endotoxemia is a condition in which blood lipopolysaccharide (LPS) levels are elevated, regardless of the presence of obvious infection. It has been suggested to lead to chronic inflammation-related diseases such as obesity, type 2 diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), pancreatitis, amyotrophic lateral sclerosis, and Alzheimer’s disease. In addition, it has attracted attention as a target for the prevention and treatment of these chronic diseases. As metabolic endotoxemia was first reported in mice that were fed a high-fat diet, research regarding its relationship with diets has been actively conducted in humans and animals. In this review, we summarize the relationship between fat intake and induction of metabolic endotoxemia, focusing on gut dysbiosis and the influx, kinetics, and metabolism of LPS. We also summarize the recent findings about dietary factors that attenuate metabolic endotoxemia, focusing on the regulation of gut microbiota. We hope that in the future, control of metabolic endotoxemia using dietary factors will help maintain human health.

nutrition & dietetics
Intestinal barrier disorders and metabolic endotoxemia in obesity: Current knowledge

Marta Potrykus,Michał Szymański,Łukasz Kaska,Agata Janczy

DOI: https://doi.org/10.2478/ahem-2022-0008

2022-01-01

Postępy Higieny i Medycyny Doświadczalnej

Abstract:Abstract The World Health Organization reports that the prevalent problem of excessive weight and obesity currently affects about 1.9 billion people worldwide and is the fifth most common death factor among patients. In view of the growing number of patients with obesity, attention is drawn to the insufficient effectiveness of behavioral treatment methods. In addition to genetic and environmental factors leading to the consumption of excess energy in the diet and the accumulation of adipose tissue, attention is paid to the role of intestinal microbiota in maintaining a normal body weight. Dysbiosis – a disorder in the composition of the gut microbiota – is mentioned as one of the contributing factors to the development of metabolic diseases, including obesity, type 2 diabetes, and cardiovascular disorders. The human gastrointestinal tract is colonized largely by a group of Gram-negative bacteria that are indicated to be a source of lipopolysaccharide (LPS), associated with inducing systemic inflammation and endotoxemia. Research suggests that disturbances in the gut microbiota, leading to damage to the intestinal barrier and an increase in circulating LPS, are implicated in obesity and other metabolic disorders. Plasma LPS and lipopolysaccharide-binding protein (LBP) levels have been shown to be elevated in individuals with excess body weight. Bariatric surgery has become a popular treatment option, leading to stable weight loss and an improvement in obesity-related conditions. The aim of this study was to characterize the factors that promote the induction of metabolic endotoxemia and its associated health consequences, along with the presentation of their changes after bariatric surgery.

medicine, research & experimental
Infection of human bone marrow stromal cells by hepatitis B virus: implications for viral persistence and the suppression of hematopoiesis.

Tathra Chai,Sharon Prior,W. Cooksley,G. K. Sing

DOI: https://doi.org/10.1093/INFDIS/169.4.871

1994-04-01

Abstract:Suspension cultures of bone marrow cells (BMC) were challenged with hepatitis B virus (HBV) to study interactions between the virus and the nonadherent and adherent BMC populations. Virus-challenged BMC developed an adherent stromal layer that differed in cellular composition from that of mock-infected cultures, showing a threefold increase in cells of the monocyte-macrophage lineage with an accompanying decrease in cells of the granulocytic lineage. Both viral envelope hepatitis B surface and core antigen expression was detected in adherent and nonadherent cell populations up to 10 days after virus challenge, which decreased thereafter. HBV DNA was still detectable in adherent cells 3 weeks after virus challenge, as shown by polymerase chain reaction analysis. These data indicate that HBV can infect not only bone marrow colony-forming cells but also the stromal cell populations involved with the regulation of hematopoiesis in vivo. Such virus-cell interactions could contribute to the immune dysfunction and bone marrow failure occasionally reported for patients with HBV infection as well as acting as an important site for HBV latency and persistence.
Microbial influence on triggering and treatment of host cancer: An intestinal barrier perspective

Henan Zhang,Junrui Wu,Na Li,Rina Wu,Wei Chen

DOI: https://doi.org/10.1016/j.bbcan.2023.188989

Abstract:Inflammatory bowel disease (IBD) is associated with complex complications that may lead to tumors. However, research on the mechanisms underlying susceptibility to chronic immune diseases and cancer pathogenesis triggered by the inflammatory environment remains limited. An imbalance in the host gut microbiota often accompanies intestinal inflammation. The delayed recovery of the dysregulated intestinal microbiota may exacerbate systemic inflammatory responses, multiorgan pathology, and metabolic disorders. This delay may also facilitate bacterial translocation. This review examined the relationship between gut barrier disruption and unbalanced microbial translocation and their impact on the brain, liver, and lungs. We also explored their potential roles in tumor initiation. Notably, the role of the intestinal microbiota in the development of inflammation is linked to the immune surveillance function of the small intestine and the repair status of the intestinal barrier. Moreover, adherence to a partially anti-inflammatory diet can aid in preventing the malignant transformation of inflammation by repairing the intestinal barrier and significantly reducing inflammation. In conclusion, enhancing intestinal barrier function may be a novel strategy for preventing and treating chronic malignancies in the intestine and other body areas.
Gut Microbiota, Inflammatory Bowel Disease, and Cancer: The Role of Guardians of Innate Immunity

Vincenzo Giambra,Danilo Pagliari,Pierluigi Rio,Beatrice Totti,Chiara Di Nunzio,Annalisa Bosi,Cristina Giaroni,Antonio Gasbarrini,Giovanni Gambassi,Rossella Cianci

DOI: https://doi.org/10.3390/cells12222654

IF: 6

2023-11-19

Cells

Abstract:Inflammatory bowel diseases (IBDs) are characterized by a persistent low-grade inflammation that leads to an increased risk of colorectal cancer (CRC) development. Several factors are implicated in this pathogenetic pathway, such as innate and adaptive immunity, gut microbiota, environment, and xenobiotics. At the gut mucosa level, a complex interplay between the immune system and gut microbiota occurs; a disequilibrium between these two factors leads to an alteration in the gut permeability, called ‘leaky gut’. Subsequently, an activation of several inflammatory pathways and an alteration of gut microbiota composition with a proliferation of pro-inflammatory bacteria, known as ‘pathobionts’, take place, leading to a further increase in inflammation. This narrative review provides an overview on the principal Pattern Recognition Receptors (PRRs), including Toll-like receptors (TLRs) and NOD-like receptors (NLRs), focusing on their recognition mechanisms, signaling pathways, and contributions to immune responses. We also report the genetic polymorphisms of TLRs and dysregulation of NLR signaling pathways that can influence immune regulation and contribute to the development and progression of inflammatory disease and cancer.

cell biology
The association of alcohol dependency with employment probability: evidence from the population survey 'Health 2000 in Finland'.

Edvard Johansson,H. Alho,U. Kiiskinen,K. Poikolainen

DOI: https://doi.org/10.1002/HEC.1201

IF: 2.395

2007-07-01

Health Economics

Abstract:In this paper, we investigate to what extent alcohol-dependent individuals fare worse in the Finnish labour market, using data from a large Finnish health survey. We used the DSM-IV criteria for alcohol dependence assessed by a composite international diagnostic interview (CIDI). We find that there are substantial disadvantages for alcohol-dependent men and women in the labour market, in the sense that they have lower employment probabilities. Treating alcohol dependence as an exogenous variable, we find that alcohol dependence is associated with decrease in the probability of full-time or part-time work of around 14 percentage points for men and 11 percentage points for women. However, accounting for endogeneity increases the negative effect to some 50 percentage points for men and to some 40 percentage points for women.
Lymph node expansion of CD4+ lymphocytes during antiretroviral therapy.

A. Lafeuillade,M. Chouraqui,G. Hittinger,C. Poggi,E. Delbeke

DOI: https://doi.org/10.1086/517326

1997-11-01

Abstract:The evolution of lymphocyte subsets was analyzed in sequential lymph nodes (LN) biopsies and compared with that in the blood of 25 human immunodeficiency virus type 1 (HIV-1)-infected patients receiving highly active antiretroviral therapy. An average of 3 biopsies were obtained from each patient, with a mean follow-up of 5.6 +/- 0.6 months. A correlation was found between the CD4:CD8 ratio in blood and in LN at baseline but not after > or = 2 months of therapy. With therapy, there was a significant increase in CD2+ cells and a much higher CD4+ cell increase and CD8+ cell decrease in LNs compared with levels in blood. A subset of patients had increased expression of Ki-67 and a decreased expression of CD8CD38 or CD3HLA-DR. Expanded CD4+ cells in LNs were mainly CD45RO+, and changes were concomitant with a decrease in LN virus load. These data demonstrate that CD4 cell reconstitution in HIV-1 infection takes place primarily in secondary lymphoid organs and is not related to a simple redistribution of cells.
Bacteroidetes promotes esophageal squamous carcinoma invasion and metastasis through LPS-mediated TLR4/Myd88/NF-κB pathway and inflammatory changes

Zhongbing Wu,Jianxin Guo,Zhenhan Zhang,Shuang Gao,Ming Huang,Yu Wang,Yushuang Zhang,Qinghuan Li,Jing Li

DOI: https://doi.org/10.1038/s41598-024-63774-6

IF: 4.6

2024-06-06

Scientific Reports

Abstract:Gut microbiota plays a crucial role in gastrointestinal tumors. Additionally, gut microbes influence the progression of esophageal cancer. However, the major bacterial genera that affect the invasion and metastasis of esophageal cancer remain unknown, and the underlying mechanisms remain unclear. Here, we investigated the gut flora and metabolites of patients with esophageal squamous cell carcinoma and found abundant Bacteroides and increased secretion and entry of the surface antigen lipopolysaccharide (LPS) into the blood, causing inflammatory changes in the body. We confirmed these results in a mouse model of 4NQO-induced esophageal carcinoma in situ and further identified epithelial–mesenchymal transition (EMT) occurrence and TLR4/Myd88/NF-κB pathway activation in mouse esophageal tumors. Additionally, in vitro experiments revealed that LPS from Bacteroides fragile promoted esophageal cancer cell proliferation, migration, and invasion, and induced EMT by activating the TLR4/Myd88/NF-κB pathway. These results reveal that Bacteroides are closely associated with esophageal cancer progression through a higher inflammatory response level and signaling pathway activation that are both common to inflammation and tumors induced by LPS, providing a new biological target for esophageal cancer prevention or treatment.

multidisciplinary sciences
From microbes to medicine: harnessing the power of the microbiome in esophageal cancer

Xiaoyan Liu,Bang Li,Liping Liang,Jimin Han,Shijie Mai,Le Liu

DOI: https://doi.org/10.3389/fimmu.2024.1450927

IF: 7.3

2024-11-13

Frontiers in Immunology

Abstract:Esophageal cancer (EC) is a malignancy with a high incidence and poor prognosis, significantly influenced by dysbiosis in the esophageal, oral, and gut microbiota. This review provides an overview of the roles of microbiota dysbiosis in EC pathogenesis, emphasizing their impact on tumor progression, drug efficacy, biomarker discovery, and therapeutic interventions. Lifestyle factors like smoking, alcohol consumption, and betel nut use are major contributors to dysbiosis and EC development. Recent studies utilizing advanced sequencing have revealed complex interactions between microbiota dysbiosis and EC, with oral pathogens such as Porphyromonas gingivalis and Fusobacterium nucleatum promoting inflammation and suppressing immune responses, thereby driving carcinogenesis. Altered esophageal microbiota, characterized by reduced beneficial bacteria and increased pathogenic species, further exacerbate local inflammation and tumor growth. Gut microbiota dysbiosis also affects systemic immunity, influencing chemotherapy and immunotherapy efficacy, with certain bacteria enhancing or inhibiting treatment responses. Microbiota composition shows potential as a non-invasive biomarker for early detection, prognosis, and personalized therapy. Novel therapeutic strategies targeting the microbiota—such as probiotics, dietary modifications, and fecal microbiota transplantation—offer promising avenues to restore balance and improve treatment efficacy, potentially enhancing patient outcomes. Integrating microbiome-focused strategies into current therapeutic frameworks could improve EC management, reduce adverse effects, and enhance patient survival. These findings highlight the need for further research into microbiota-tumor interactions and microbial interventions to transform EC treatment and prevention, particularly in cases of late-stage diagnosis and poor treatment response.

immunology
How Gut Microbiota May Influence Colorectal Cancer Metastatic Potential

Irene Mignini,Giulia Piccirilli,Linda Galasso,Fabrizio Termite,Giorgio Esposto,Maria Elena Ainora,Antonio Gasbarrini,Maria Assunta Zocco

DOI: https://doi.org/10.3390/jcm13020420

IF: 3.9

2024-01-13

Journal of Clinical Medicine

Abstract:The gut microbiota's influence on human tumorigenesis is a burning topic in medical research. With the new ontological perspective, which considers the human body and its pathophysiological processes as the result of the interaction between its own eukaryotic cells and prokaryotic microorganisms living in different body niches, great interest has arisen in the role of the gut microbiota on carcinogenesis. Indeed, dysbiosis is currently recognized as a cancer-promoting condition, and multiple molecular mechanisms have been described by which the gut microbiota may drive tumor development, especially colorectal cancer (CRC). Metastatic power is undoubtedly one of the most fearsome features of neoplastic tissues. Therefore, understanding the underlying mechanisms is of utmost importance to improve patients' prognosis. The liver is the most frequent target of CRC metastasis, and new evidence reveals that the gut microbiota may yield an effect on CRC diffusion to the liver, thus defining an intriguing new facet of the so-called "gut-liver axis". In this review, we aim to summarize the most recent data about the microbiota's role in promoting or preventing hepatic metastasis from CRC, highlighting some potential future therapeutic targets.

medicine, general & internal
Within-session reliability and smallest real difference of muscle strength following nerve transfers in patients with brachial plexus injuries.

Y. Tsai,Y. Tu,C. Hsiao,F. Su

DOI: https://doi.org/10.1016/j.jhsa.2015.01.043

2015-06-01

Abstract:
Gut Microbiota Modulation in the Context of Immune-Related Aspects of Lactobacillus spp. and Bifidobacterium spp. in Gastrointestinal Cancers

Karolina Kaźmierczak-Siedlecka,Giandomenico Roviello,Martina Catalano,Karol Polom

DOI: https://doi.org/10.3390/nu13082674

IF: 5.9

2021-07-31

Nutrients

Abstract:Accumulating evidence has revealed the critical roles of commensal microbes in cancer progression and recently several investigators have evaluated the therapeutic effectiveness of targeting the microbiota. This gut microbiota-related approach is especially attractive in the treatment of gastrointestinal cancers. Probiotics supplementation is a microbiota-targeted strategy that appears to improve treatment efficacy; Lactobacillus spp. and Bifidobacterium spp. are among the most commonly used probiotic agents. These bacteria seem to exert immunomodulatory effects, impacting on the immune system both locally and systemically. The gut microbiota are able to affect the efficiency of immunotherapy, mainly acting as inhibitors at immune checkpoints. The effects of immunotherapy may be modulated using traditional probiotic strains and/or next generation probiotics, such as Akkermansia municiphila. It is possible that probiotics might enhance the efficiency of immunotherapy based on PD-1/PD-L1 and CTLA-4 but more data are needed to confirm this speculation. Indeed, although there is experimental evidence for the efficacy of several strains, the health-promoting effects of numerous probiotics have not been demonstrated in human patients and furthermore the potential risks of these products, particularly in oncologic patients, are rarely mentioned.

nutrition & dietetics
From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?

Giovanni Vitale,Alessandra Dicitore,Luigi Barrea,Emilia Sbardella,Paola Razzore,Severo Campione,Antongiulio Faggiano,Annamaria Colao,Manuela Albertelli,Barbara Altieri,Filomena Bottiglieri,Federica De Cicco,Sergio Di Molfetta,Giuseppe Fanciulli,Tiziana Feola,Diego Ferone,Francesco Ferraù,Marco Gallo,Elisa Giannetta,Federica Grillo,Erika Grossrubatscher,Elia Guadagno,Valentina Guarnotta,Andrea M. Isidori,Andrea Lania,Andrea Lenzi,Fabio Lo Calzo,Pasquale Malandrino,Erika Messina,Roberta Modica,Giovanna Muscogiuri,Luca Pes,Genoveffa Pizza,Riccardo Pofi,Giulia Puliani,Carmen Rainone,Laura Rizza,Manila Rubino,Rosa Maria Ruggieri,Franz Sesti,Mary Anna Venneri,Maria Chiara Zatelli,

DOI: https://doi.org/10.1007/s11154-020-09589-y

2020-09-15

Reviews in Endocrine and Metabolic Disorders

Abstract:Abstract Gut microbiota is represented by different microorganisms that colonize the intestinal tract, mostly the large intestine, such as bacteria, fungi, archaea and viruses. The gut microbial balance has a key role in several functions. It modulates the host’s metabolism, maintains the gut barrier integrity, participates in the xenobiotics and drug metabolism, and acts as protection against gastro-intestinal pathogens through the host’s immune system modulation. The impaired gut microbiota, called dysbiosis, may be the result of an imbalance in this equilibrium and is linked with different diseases, including cancer. While most of the studies have focused on the association between microbiota and gastrointestinal adenocarcinomas, very little is known about gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs). In this review, we provide an overview concerning the complex interplay between gut microbiota and GEP NENs, focusing on the potential role in tumorigenesis and progression in these tumors.

endocrinology & metabolism
Intersections between innate immune response and gastric cancer development

Franz Villarroel-Espindola,Troy Ejsmentewicz,Roxana Gonzalez-Stegmaier,Roddy A Jorquera,Esteban Salinas

DOI: https://doi.org/10.3748/wjg.v29.i15.2222

IF: 5.374

2023-04-21

World Journal of Gastroenterology

Abstract:Worldwide, gastric cancer (GC) is the fifth most commonly diagnosed malignancy. It has a reduced prevalence but has maintained its poor prognosis being the fourth leading cause of deaths related to cancer. The highest mortality rates occur in Asian and Latin American countries, where cases are usually diagnosed at advanced stages. Overall, GC is viewed as the consequence of a multifactorial process, involving the virulence of the Helicobacter pylori (H. pylori) strains, as well as some environmental factors, dietary habits, and host intrinsic factors. The tumor microenvironment in GC appears to be chronically inflamed which promotes tumor progression and reduces the therapeutic opportunities. It has been suggested that inflammation assessment needs to be measured qualitatively and quantitatively, considering cell-infiltration types, availability of receptors to detect damage and pathogens, and presence or absence of aggressive H. pylori strains. Gastrointestinal epithelial cells express several Toll-like receptors and determine the first defensive line against pathogens, and have been also described as mediators of tumorigenesis. However, other molecules, such as cytokines related to inflammation and innate immunity, including immune checkpoint molecules, interferon-gamma pathway and NETosis have been associated with an increased risk of GC. Therefore, this review will explore innate immune activation in the context of premalignant lesions of the gastric epithelium and established gastric tumors.

gastroenterology & hepatology
Gut Microbiota-Mediated Modulation of Cancer Progression and Therapy Efficacy

Peng Cheng,Peiliang Shen,Yunlong Shan,Yu Yang,Rui Deng,Wenxing Chen,Yin Lu,Zhonghong Wei

DOI: https://doi.org/10.3389/fcell.2021.626045

IF: 5.5

2021-09-08

Frontiers in Cell and Developmental Biology

Abstract:The role of gut microbiota in the development of various tumors has been a rising topic of public interest, and in recent years, many studies have reported a close relationship between microbial groups and tumor development. Gut microbiota play a role in host metabolism, and the positive and negative alterations of these microbiota have an effect on tumor treatment. The microbiota directly promote, eliminate, and coordinate the efficacy of chemotherapy drugs and the toxicity of adjuvant drugs, and enhance the ability of patients to respond to tumors in adjuvant immunotherapy. In this review, we outline the significance of gut microbiota in tumor development, reveal its impacts on chemotherapy and immunotherapy, and discover various potential mechanisms whereby they influence tumor treatment. This review demonstrates the importance of intestinal microbiota-related research for clinical tumor treatment and provides additional strategy for clinical assistance in cancer treatment.

cell biology,developmental biology
The Crosstalk between Microbiome and Immune Response in Gastric Cancer

Rihab Nasr,Ali Shamseddine,Deborah Mukherji,Farah Nassar,Sally Temraz

DOI: https://doi.org/10.3390/ijms21186586

IF: 5.6

2020-09-09

International Journal of Molecular Sciences

Abstract:Gastric cancer is the end result of a complex interplay between host genetics, environmental factors, and microbial factors. The link between gut microbiome and gastric cancer has been attributed to persistent activation of the host’s immune system by gut microbiota. The end result of this dysregulated interaction between host epithelium and microbes is a state of chronic inflammation. Gut bacteria can promote anti-tumor immune responses through several mechanisms. These include triggering T-cell responses to bacterial antigens that can cross-react with tumor antigens or cause tumor-specific antigen recognition; engagement of pattern recognition receptors that mediate pro-immune or anti-inflammatory effects or via small metabolites that mediate systemic effects on the host. Here we review the role of the gut microbiome including H. pylori and non-H. pylori gastric bacteria, the immune response, and immunotherapy using checkpoint inhibitors. We also review the evidence for cross talk between the gut microbiome and immune response in gastric cancer.

biochemistry & molecular biology,chemistry, multidisciplinary
Role of the Microbiome in the Diagnosis and Management of Gastroesophageal Cancers

Federica Mascaretti,Salman Haider,Chiara Amoroso,Flavio Caprioli,Daryl Ramai,Michele Ghidini

DOI: https://doi.org/10.1007/s12029-024-01021-x

Abstract:Purpose: Stomach and esophageal cancers are among the highest mortality from cancers worldwide. Microbiota has an interplaying role within the human gastrointestinal (GI) tract. Dysbiosis occurs when a disruption of the balance between the microbiota and the host happens. With this narrative review, we discuss the main alterations in the microbiome of gastroesophageal cancer, revealing its potential role in the pathogenesis, early detection, and treatment. Results: Helicobacter pylori plays a major role the development of a cascade of preneoplastic conditions ranging from atrophic gastritis to metaplasia and dysplasia, ultimately culminating in gastric cancer, while other pathogenic agents are Fusobacterium nucleatum, Bacteroides fragilis, Escherichia coli, and Lactobacillus. Campylobacter species (spp.)'s role in the progression of esophageal adenocarcinoma may parallel that of Helicobacter pylori in the context of gastric cancer, with other esophageal carcinogenic agents being Escherichia coli, Bacteroides fragilis, and Fusobacterium nucleatum. Moreover, gut microbiome could significantly alter the outcomes of chemotherapy and immunotherapy. The gut microbiome can be modulated through interventions such as antibiotics, probiotics, or prebiotics intake. Fecal microbiota transplantation has emerged as a therapeutic strategy as well. Conclusions: Nowadays, it is widely accepted that changes in the normal gut microbiome causing dysbiosis and immune dysregulation play a role gastroesophageal cancer. Different interventions, including probiotics and prebiotics intake are being developed to improve therapeutic outcomes and mitigate toxicities associated with anticancer treatment. Further studies are required in order to introduce the microbiome among the available tools of precision medicine in the field of anticancer treatment.

TPO for ITP in pregnancy.

Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity

Gut Barrier Dysfunction and Bacterial Lipopolysaccharides in Colorectal Cancer

Iterative learning control for output-constrained systems with both parametric and nonparametric uncertainties

Regulation of Gut Microbiota and Metabolic Endotoxemia with Dietary Factors

Intestinal barrier disorders and metabolic endotoxemia in obesity: Current knowledge

Infection of human bone marrow stromal cells by hepatitis B virus: implications for viral persistence and the suppression of hematopoiesis.

Microbial influence on triggering and treatment of host cancer: An intestinal barrier perspective

Gut Microbiota, Inflammatory Bowel Disease, and Cancer: The Role of Guardians of Innate Immunity

The association of alcohol dependency with employment probability: evidence from the population survey 'Health 2000 in Finland'.

Lymph node expansion of CD4+ lymphocytes during antiretroviral therapy.

Bacteroidetes promotes esophageal squamous carcinoma invasion and metastasis through LPS-mediated TLR4/Myd88/NF-κB pathway and inflammatory changes

From microbes to medicine: harnessing the power of the microbiome in esophageal cancer

How Gut Microbiota May Influence Colorectal Cancer Metastatic Potential

Within-session reliability and smallest real difference of muscle strength following nerve transfers in patients with brachial plexus injuries.

Gut Microbiota Modulation in the Context of Immune-Related Aspects of Lactobacillus spp. and Bifidobacterium spp. in Gastrointestinal Cancers

From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?

Intersections between innate immune response and gastric cancer development

Gut Microbiota-Mediated Modulation of Cancer Progression and Therapy Efficacy

The Crosstalk between Microbiome and Immune Response in Gastric Cancer

Role of the Microbiome in the Diagnosis and Management of Gastroesophageal Cancers